

20 **Abstract:**

21 Immunity to SARS-CoV-2 in COVID-19 cases has diversified due to complex combinations of
22 exposure to vaccination and infection. Elucidating the drivers for upgrading neutralizing activity
23 to SARS-CoV-2 in COVID-19 cases with pre-existing immunity will aid in understanding
24 immunity to SARS-CoV-2 and improving COVID-19 booster vaccines with enhanced cross-
25 protection against antigenically distinct variants. This study revealed that the magnitude and
26 breadth of neutralization responses to SARS-CoV-2 infection in breakthrough infections are
27 determined by upper respiratory viral load and vaccination-infection time interval, but not by the
28 lineage of infecting viruses. Notably, the time interval, but not the viral load, may play a critical
29 role in expanding the breadth of neutralization to SARS-CoV-2. This illustrates the importance of
30 dosing interval optimization in addition to antigen design in the development of variant-proof
31 booster vaccines.

32
33 **One-Sentence Summary:** Viral load and infection timing define the magnitude and breadth of
34 SARS-CoV-2 neutralization after breakthrough infection.

35

36

37

38 **Main Text:**

39 The proportion of individuals in the population with antiviral immunity to severe acute respiratory
40 syndrome coronavirus type 2 (SARS-CoV-2) has increased dramatically due to the surge in
41 coronavirus disease 2019 (COVID-19) cases and extensive worldwide vaccine campaigns.
42 Nevertheless, the cases continue to increase, causing significant morbidity and mortality
43 worldwide, due to the emergence of variants of concern (VOCs) with varying levels of increased
44 transmissibility and resistance to existing immunity; thus, highlighting the necessity to develop
45 next-generation COVID-19 vaccines. These vaccines must induce a durable and broad breadth of
46 protective immunity covering all SARS-CoV-2 variants (1). Many open questions remain about
47 how to induce high quality immunity that suppresses viruses with distinct antigenicity. A better
48 understanding of immune responses to SARS-CoV-2 infection will ultimately yield better vaccine
49 designs.

50 The most recently emerged VOC, the Omicron (B.1.1.529 lineage) variant, has spread rapidly
51 worldwide at an unprecedented pace and with rapidly expanding viral genome diversity (2). As of
52 March 2022, the BA.1, BA.1.1, and BA.2 sub-lineages account for the major Omicron sub-
53 lineages (2). BA.1 is characterized by approximately 30 amino acid mutations, three short
54 deletions, and one insertion in the spike protein; 15 mutations are located in the receptor-binding
55 domain (RBD) and induce evasion of humoral immunity induced by prior infection or vaccination
56 (3-5). Although BA.1 and BA.1.1 are presently the predominant Omicron variants, the relative
57 incidence of BA.2 has increased rapidly in many countries and regions (6). BA.2, containing 11
58 spike protein mutations different from BA.1, has dramatically altered viral immune evasion
59 capabilities, raising a serious global public health concern as a potential source of viral surge.
60 Despite the high capability for humoral immunity evasion seen in BA.1, cross-neutralizing activity

61 against BA.1 is elicited in booster vaccinees (3, 7-9). Research groups, including our own, report
62 that cross-neutralizing activity against BA.1 and BA.1.1 is elicited in COVID-19 vaccine
63 breakthrough infections (10-13).

64 Notably, convalescent sera from patients with breakthrough infections show lower or more
65 variable neutralizing antibody titers against BA.1 than in those receiving booster vaccinations.
66 Moreover, the time interval from vaccination to infection determines the induction of cross-
67 neutralization to BA.1 and BA.1.1 variants; a longer interval contributing a greater induction of
68 cross-neutralizing antibodies (10, 14). In contrast to booster vaccination, where both the dose and
69 interval between vaccinations are controlled, the time interval between vaccination and
70 breakthrough infection is not controlled resulting in diverse humoral immune responses against
71 SARS-CoV-2 variants in breakthrough infections. However, other factors, such as symptoms, the
72 infected viral strain, and viral replication, are expected to impact the immune response to SARS-
73 CoV-2 infection. Primary drivers of humoral immune responses to SARS-CoV-2 in breakthrough
74 infections have not been fully elucidated. Research in this area will provide fundamental insight
75 into better vaccine designs, especially for booster vaccines.

76 Herein, we evaluated relationships between the amount of cross-neutralization activity to
77 SARS-CoV-2 variants at acute and convalescent phases, upper respiratory tract viral load, and
78 vaccination-infection time interval in non-Omicron breakthrough infection, as well as other case
79 characteristics, and identified the key drivers of the magnitude and breadth of humoral immune
80 responses to SARS-CoV-2 variants in individuals with immune histories due to combinations of
81 vaccination and breakthrough infection.

82

83 **Results and Discussion**

84 ***Upper respiratory viral load and serum cross-neutralizing activity***

85 We performed virological characterization of 220 breakthrough SARS-CoV-2 infected individuals,
86 diagnosed 14 days after their second vaccination, using upper respiratory specimens collected
87 within four days after diagnosis or disease onset (interquartile range; 0-0 days) (Tables S1, S2).
88 Spike-mutation detection polymerase chain reaction (PCR) and viral genome analysis showed that
89 most infected viruses were Delta or Alpha variants (Table S1). Viral RNA loads and infectious
90 viral titers in upper respiratory specimens were significantly higher in Delta infected individuals
91 than in Alpha infected individuals (Fig. 1A). Viral RNA loads and infectious viral titers were
92 positively correlated to the same extent in both variants (Fig. S1A), suggesting no difference in
93 the relationship between infectious viral amount and viral RNA levels between the variants. These
94 results suggest that Delta variant replicates more efficiently in the upper respiratory tract in
95 breakthrough infected individuals, consistent with previous reports (15, 16).

96 Sera from the enrolled cases were also obtained at one or two additional time points after infection.
97 We defined the acute phase as within four days after diagnosis (four days after onset for cases
98 diagnosed after onset) and the convalescent phase was defined as seven days after diagnosis or
99 onset, based on the dynamics of anti-spike (S) RBD and anti-nucleoprotein (N) antibody titers (Fig.
100 S1B). We excluded cases positive for anti-N antibody in the acute phase because they had a history
101 of SARS-CoV-2 infection prior to breakthrough infection. Additionally, cases with acute phase
102 anti-S RBD antibody titers <10 U/mL were excluded from this analysis because they were
103 considered as low responders to COVID-19 vaccination. Following this, 26 cases with sera
104 collected in the acute phase and 51 cases with sera collected in the convalescent phase (16 of whom
105 had both acute and convalescent phase sera) were enrolled for further analysis. Serum neutralizing
106 activity in these cases was measured using pseudovirus- or live virus-based assays (Figs. 1B, S1C).

107 Neutralization titers to the ancestral and BA.2 strains were strongly correlated (Fig. S1D).

108 Neutralization titers determined by pseudovirus-based assays were used for further analyses.

109 Neutralizing activity for all variants was higher in the convalescent phase than in the acute phase.

110 (Figs. 1B, S1C). Acute phase sera showed lower neutralizing activity to Beta, Delta, BA.1, and

111 BA.2 variants than to ancestral strain. Furthermore, convalescent phase sera showed lower

112 neutralizing activity to Beta, BA.1, and BA.2 variants than to the ancestral strain. Notably, no

113 obvious differences were found in neutralizing activity between BA.1 and BA.2 in both acute and

114 convalescent phase sera, suggesting negligible antigenic difference between BA.1 and BA.2 in

115 non-Omicron breakthrough sera. Acute and convalescent neutralization titers were lower to BA.2

116 than to ancestral strain (using live virus-based assays) (Fig. S1C), which confirmed the results

117 obtained in the pseudoviruses-based assay. Convalescent phase sera from Delta breakthrough

118 infections showed higher neutralizing activity against ancestral and Beta variants than sera from

119 Alpha breakthrough infections, and both demonstrated equivalent neutralizing activity against

120 Alpha and Delta variants. No apparent differences in neutralizing activity for BA.1 or BA.2 were

121 observed between sera from Delta and Alpha breakthrough infections (Fig. S1E), suggesting that

122 neutralizing antibodies against the infected variant in breakthrough cases were not necessarily

123 induced preferentially over neutralizing antibodies against other variants.

124 To understand the impact of viral replication in breakthrough infections on antibody response, we

125 analyzed the relationship between upper respiratory viral load and neutralizing activity to each

126 variant in the acute or convalescent phase (Fig. 1C). In the acute phase, serum neutralization titers

127 against ancestral strain and Alpha variant showed a significant negative correlation with upper

128 respiratory viral load; similar trends were observed for acute phase serum neutralization titers

129 against Delta variant; some serum neutralization titers against Beta, BA.1, and BA.2 variants in

130 the acute phase were below detection limits, and precise correlations were not determined.
131 However, convalescent phase serum neutralizing titers against all variants correlated positively
132 with upper respiratory viral load. Notably, the relationship between upper respiratory viral load
133 and acute phase neutralization was exactly opposite from the relationship between upper
134 respiratory viral load and convalescent phase neutralization. Moreover, the increase in neutralizing
135 activity against all variants from the acute to convalescent phases (using paired sera) was strongly
136 positively correlated with upper respiratory viral load (Fig. 1D), indicating that lower levels of
137 neutralizing antibodies during the acute phase of breakthrough infections are associated with
138 higher viral replication levels in the upper respiratory tract, and that higher viral replication levels
139 in the upper respiratory tract at the time of breakthrough infection induce a greater number of
140 cross-neutralizing antibodies against a wide range of variants including Omicron variants in non-
141 Omicron breakthrough infections. Further, it has been reported in non-human primate infectious
142 models and observational studies on COVID-19 vaccine breakthrough infections that low levels
143 of neutralizing antibodies prior to infection allow for efficient viral replication in the upper
144 respiratory tract (17-19). This is consistent with the present results showing an obvious relationship
145 between acute-phase neutralizing activity and viral load. It has also been reported that lower viral
146 load in the upper respiratory tract tends to induce more neutralizing antibodies in unvaccinated
147 SARS-CoV-2-infected patients (20), which is contrary to the present results showing a positive
148 relationship between convalescent phase neutralizing activity and viral load in breakthrough
149 infections. This suggests that the induction of neutralizing antibodies in breakthrough infections
150 involves an interaction between preexisting immunity obtained through vaccination and viral
151 replication during breakthrough infection.

152

153 ***Cross-neutralizing activity***

154 Previously, we reported that the cross-neutralizing activity of breakthrough convalescence sera
155 against SARS-CoV-2 variants correlates with the vaccination-infection time interval (10).
156 However, the induction of antiviral immunity is expected to involve additional factors, including
157 age, sex, symptomology, the viral lineage, and viral replication. To explore the primary factors
158 influencing neutralizing activity against each variant in breakthrough infections, we calculated
159 correlation coefficients for each combination of factors: antibody titers, neutralization titers, age,
160 sex, viral lineage (Delta, Alpha), viral load, the time interval from vaccination to infection, and the
161 presence or absence of symptoms (Fig. 2A). In the convalescent phase, all neutralization titers
162 were strongly and positively correlated. Most neutralization titers were also positively correlated
163 in the acute phase. However, neutralization titers in acute phase sera did not correlate with
164 neutralization titers in the convalescent phase sera for any variant (Fig. 2A), suggesting that
165 neutralizing activity in the acute phase does not determine subsequent antibody responses in the
166 convalescent phase. Additionally, sex, age, and symptom onset showed no clear correlation with
167 neutralization titers in convalescent phase sera. Delta variant infection was positively correlated
168 with neutralization titers to ancestral and Beta strains only, confirming the results shown above
169 (Fig. S1E). Conversely, the vaccination-infection interval was positively correlated with
170 neutralization titers to ancestral, Beta, BA.1, and BA.2 strains in convalescent phase sera.
171 Additionally, upper respiratory viral load correlated strongly with neutralization titers against all
172 variants in convalescent phase sera, suggesting that upper respiratory viral load at the time of
173 diagnosis influences antibody responses in the convalescent phase following breakthrough
174 infection.

175 To independently evaluate the impacts of these two different factors on neutralizing activity, we
176 performed a multiple regression analysis on three parameters: neutralization titers for each variant,
177 viral load, and the vaccination-infection time interval (Table 1). Further we evaluated the slope-

178 coefficients for viral load and vaccination-infection time interval on neutralization titers for each
179 variant. The coefficients for viral load were significant for neutralization titers against ancestral,
180 Alpha, Beta, Delta, and BA.2 strains (but not for BA.1). However, although the coefficients for
181 vaccination-infection time interval were significant for neutralization titers against BA.1, and
182 BA.2, they were not for the ancestral, Alpha, Beta, or Delta strains. Moreover, three-dimensional
183 plots utilizing neutralization titers to each variant, viral load, and the vaccination-infection time
184 interval as independent variables revealed that the regression plane skewed more towards viral
185 load in neutralizing activity to the ancestral strain, Alpha, and Delta, and more towards the
186 vaccination-infection time interval in neutralizing activity to Beta, BA.1, and BA.2 (Fig. 2B).
187 These results suggest that upper respiratory viral load more strongly determines convalescent
188 phase neutralizing activity to ancestral, Alpha, Beta, and Delta variants (vs. BA.1 and BA.2).
189 Contrarily, the vaccination-infection time interval more strongly determined the convalescent
190 phase neutralizing activity to BA.1, and BA.2. Two independent factors (upper respiratory viral
191 load and the vaccination-infection time interval) showed differing magnitude of impact for each
192 variant on the induction of variant neutralizing antibodies in breakthrough infections.

193

194 *Antigenic distances*

195 To better understand the overall picture regarding the potency of cross-neutralization, evaluating
196 broadness of the neutralizing antigenicity is crucial. Antigenic differences among variants
197 recognized by each serum were calculated as the distances between each variant and serum on
198 antigenic maps (21, 22). Antigens and sera are positioned relative to each other on an antigenic
199 map, and antigenic distances between antigens may vary depending on the nature of the sera used
200 in the analysis. The distance between variants recognized as antigenically different is greater than

201 that between variants recognized as antigenically similar. Additionally, a shorter distance from a
202 serum to a variant on an antigenic map indicates higher neutralizing activity compared to other
203 serum-variant pairs. Calculating the distance between each variant and serum on an antigenic map
204 is useful for comparing the breadth of neutralizing activity for each serum. To evaluate how
205 distances between variants and sera on an antigenic map change depending on nature of the sera,
206 an antigenic map was generated using sera obtained from individuals who were vaccinated twice
207 (2vax) or three times (3vax) with BNT162b2 (the Pfizer/BioNTech mRNA vaccine) (Fig. 3A).

208 For 2vax sera, neutralization titers against Beta, BA.1, and BA.2 were more than 10-fold lower
209 than titers against ancestral strain (Fig. 3A). The positions of each variant were scattered on the
210 antigenic map, with variants being spaced far apart (Fig. 3B).

211 Conversely, for 3vax sera, there was only an approximately four-fold reduction in neutralization
212 titers against Beta, BA.1, and BA.2 variants compared with that against ancestral strain (Fig. 3A).
213 All variants (including BA.1 and BA.2) were spaced close together (Fig. 3B), suggesting that sera
214 from individuals with booster dose vaccinations possesses an expanded breadth of neutralizing
215 activity against SARS-CoV-2 variants (including BA.1 and BA.2), and confirming that distances
216 between each variant on the antigen map vary in accordance with nature of the sera used in the
217 analysis.

218 Antigen maps were generated using acute phase or convalescent phase sera from individuals with
219 breakthrough infections (Fig. 3B). There were no obvious differences in the distances between
220 variants in the acute and convalescent phases of breakthrough infection, and there was more
221 variation in the serum positions in both the acute and convalescent phases in breakthrough
222 infections than in maps depicting 2vax and 3vax sera, suggesting that the breadth of neutralizing
223 activity in breakthrough sera is as diverse from case to case as the magnitude of neutralizing

224 activity. Furthermore, the antigenic distances between the BA.1 and BA.2 variants on the antigenic
225 maps generated from both the breakthrough infection and 3vax sera were shorter than those
226 generated using 2vax sera (Fig. 3B), suggesting that a third exposure (due to vaccination or
227 breakthrough infection) may have the effect of shrinking the antigenic differences between the
228 variants recognized as antigenically distinct viruses by 2vax sera. The antigenicity of the BA.1 and
229 BA.2 variants has been shown to differ in naïve infected hamster convalescence sera (23).
230 Contrastingly, human observational studies have reported that sera from individuals receiving
231 booster vaccines shows similar neutralizing activity against BA.1 and BA.2 variants, and that
232 vaccine effectiveness in booster vaccinees did not differ between BA.1 and BA.2 variants (24-26).
233 Moreover, a decrease in the antigenic distance between BA.1 and D614G variants in sera from
234 booster vaccinees was reported in a prior study (21). These previous findings are consistent with
235 our findings.

236 We noted that BA.2 spike introduced 11 amino acid mutations differing from BA.1 spike. The
237 similarity in antigenicity between BA.1 and BA.2 variants recognized by 3vax and breakthrough
238 infection sera suggests that the highly cross-neutralizing antibody induced by a third exposure (i.e.,
239 by vaccination or breakthrough infection) might overcome the effects of amino acid mutations
240 specific to BA.2 and BA.1 spikes.

241 242 ***Vaccination-infection time interval and breadth of neutralizing activity***

243 To compare the neutralizing breadth for each serum (obtained from vaccinees with or without
244 breakthrough infection), an antigenic map was generated using 2vax, 3vax, and breakthrough
245 infection sera (Fig. 4A); 3vax sera tended to be located closer to Beta, BA.1, and BA.2 than 2vax
246 sera (Fig. 4A). We calculated variant-serum distances between each serum to each variant. In the

247 heatmap clustering individual variant-serum distances, Beta, BA.1, and BA.2 were clustered in an
248 antigenic group (antigenic group 2; vs. antigenic group 1, which included ancestral strain, Alpha,
249 and Delta variants) (Fig. 4B), suggesting that Beta, BA.1, and BA.2 are antigenically distinct from
250 ancestral strain. Additionally, almost all 3vax sera (but not 2vax sera) were classified as type 3
251 serum, with a short variant-serum distance for all variants (Fig. 4B), suggesting that booster
252 vaccination conferred a greater breadth of neutralizing activity against SARS-CoV-2 (including
253 antigenically distinct variants). However, in breakthrough infection sera, neither acute nor
254 convalescent phase sera were classified into a specific serum type (Fig. 4B), suggesting that the
255 breadth of neutralizing activity in breakthrough infection was diversified from case to case.

256 Next, variant-serum distances were compared for 2vax, 3vax, acute phase, and convalescent phase
257 sera (Fig. 4C). A shorter variant-serum distance indicated a higher degree of neutralization. The
258 variant-serum distances for the ancestral strain in 2vax, 3vax, acute phase, and convalescent phase
259 sera were shorter than those for the other variants and did not differ among serum sources.
260 Conversely, variant-serum distances for antigenically distinct variants, such as Beta, BA.1, and
261 BA.2, were relatively longer than those for the ancestral, Alpha, and Delta variants. The variant-
262 serum distances for 3vax, acute phase, and convalescent phase sera (in regard to the antigenically
263 distinct variants) were statistically significantly shorter than for 2vax, suggesting that antibodies
264 with an expanded breadth of neutralization covering antigenically distinct variants were induced
265 in booster dose vaccinees in the acute and convalescent phases of breakthrough infection.

266 Following this, we evaluated the impact of the infecting viral lineage on variant-serum distances,
267 and found no differences in variant-serum distance in either the acute or the convalescent phase
268 (Fig. S2A). This suggests that the breadth of serum neutralization does not vary between Alpha
269 and Delta breakthrough infections, and that Alpha and Delta breakthrough infections (antigenic

270 group 1) equally impact the extent of the breadth of neutralization against different antigenic
271 variants (antigenic group 2).

272 Moreover, to assess the effect of the time interval on the breadth of neutralization, breakthrough
273 sera were divided into short (early breakthrough) and long (late breakthrough) time interval groups,
274 and variant-serum distances were compared for each variant and serum. The variant-serum
275 distances for BA.1 and BA.2 in the sera of the late breakthrough group were shorter than those in
276 the early breakthrough group in convalescent phase sera (Fig. S2B). Intriguingly, the variant-serum
277 distance did not change between the early and late breakthrough groups for either variant in acute
278 phase sera (Fig. S2B). These observations suggest that the time interval from vaccination to
279 infection strongly determines the breadth of neutralizing antibodies in the convalescent phase
280 induced after breakthrough infection.

281 We evaluated the correlation between variant-serum distances in breakthrough infection sera, the
282 vaccination-infection time interval, and the upper respiratory viral load (Figs. 4D, 4E). Variant-
283 serum distances for the ancestral, Alpha, and Delta strains did not correlate with the vaccination-
284 infection time interval, while the variant-serum distances for antigenically distinct variants
285 correlated negatively. Upper respiratory viral load did not correlate with variant-serum distances
286 for any variants. These results suggest that the vaccination-infection time interval acts as a primary
287 determinant of variant-serum distances for antigenically distinct variants from the vaccine antigen
288 and ancestral strain without being limited by the antigenicity of the infecting virus or viral
289 replication, and that a longer time interval contributes to expanding the breadth of neutralization
290 regarding antigenically distinct variants.

291 COVID-19-vaccine breakthrough infections were previously found to elicit robust cross-
292 neutralizing antibody responses against several SARS-CoV-2 variants, which were largely

293 recalled from memory B cells induced by previous vaccinations (27). mRNA vaccines induce a
294 persistent germinal center B cell response in the draining lymph nodes at least 12 weeks after the
295 second vaccine dose, enabling the generation of robust humoral immunity (28). Memory B cells
296 recognizing Omicron and other variants are known to proliferate after the second vaccination (29,
297 30) and memory B cells recognizing the Omicron spike proliferate after the third vaccination (31).
298 These findings support the contention that a third exposure increases the B cell population
299 producing antibodies with high cross-neutralizing potency. Indeed, affinity maturation of IgG
300 antibodies to the spike-protein-conserved region persisted for more than three months after SARS-
301 CoV-2 infection in a prior study (32). Furthermore, cross-neutralization ability against
302 antigenically distant variants was induced in a group with a longer first-to-second vaccination
303 interval (33). Our study and previous findings support the importance of the time interval from
304 vaccination in the progression of the breadth of humoral immunity to SARS-CoV-2 regarding both
305 booster vaccinations and breakthrough infections.

306 Moreover, we showed that the upper respiratory viral load in Delta or Alpha (i.e., antigenic group
307 1) breakthrough infected individuals determined the resulting increase in the magnitude of the
308 humoral immune response to SARS-CoV-2, including to variants belonging to antigenic group 2
309 (Fig. 1). This finding indicates that the viral replication level in the upper respiratory tract impacts
310 neutralizing antibody production. Viral replication can modulate antiviral immunity through
311 synthesizing viral antigens that serve as immunogens for inducing antiviral antibodies. Intriguingly,
312 the effect of upper respiratory viral load on neutralizing antibody production in Delta/Alpha variant
313 breakthrough infections was seen for both antigenically similar variants (ancestral, Alpha, and
314 Delta variants) and antigenically distinct variants (Beta, BA.1, BA.2) across the antigenic barrier.
315 This suggests that viral antigens supplied by upper respiratory viral replication in breakthrough
316 infected cases might be sufficient to overcome the antigenic barrier by stimulating B cells against

317 neutralizing epitopes that are conserved among variants in individuals infected after a sufficient
318 time interval. Additionally, suggesting the potentially different approach to rational antigen design
319 in booster vaccine development aimed at inducing a broad breadth of protective immunity (i.e.,
320 covering all SARS-CoV-2 variants). The time interval rather than the upper respiratory viral load
321 was shown to expand the breadth of neutralization. However, further evaluation of the impact of
322 upper respiratory viral load on the expansion of neutralization breadth in breakthrough infections
323 with antigenically distinct viruses relative to the current vaccine strain is needed to fully elucidate
324 the role of viral replication as a key driver of upgrading neutralizing activity in individuals with
325 breakthrough infections.

326 Despite the overall strengths of this study, it has several limitations. First, the cases enrolled in this
327 study were limited to breakthrough cases infected with the Alpha or Delta variant, and did not
328 include cases infected with the Omicron variant. If the antigenicity of the Omicron variant is
329 distinct from the current vaccine strain, we cannot rule out the possibility that viral load may affect
330 neutralization breadth in breakthrough cases occurring due to Omicron variants. Second, the
331 disease severity of the breakthrough cases enrolled in this study was predominantly biased toward
332 asymptomatic and mild cases. However, COVID-19 disease severity is reported to be an important
333 determinant of antibody induction in unvaccinated individuals (20, 32). Third, since acute phase
334 sera from individuals with breakthrough infections showed a low neutralization titer (even against
335 the ancestral virus) in our investigation, we could not determine an accurate fold reduction in the
336 neutralizing antibody titer or an accurate correlation coefficient against respiratory viral load.
337 Fourth, we did not assess T-cell immunity against SARS-CoV-2, which contributes to protection
338 when antibody titers are low in non-human primate models (19) and may correlate with protection
339 against severe disease. Fifth, there was no individual who experienced breakthrough infection after
340 the booster dose enrolled this study. Sixth, breakthrough infection sera for individuals'

341 vaccination-infection time intervals of more than four months were not available in this study, and
342 the interval that maximizes cross-neutralization potency remains unknown. Finally, our
343 investigation did not evaluate the actual risk of reinfection by SARS-CoV-2 in individuals with a
344 history of breakthrough infection, although there is evidence that neutralizing antibody titers can
345 be a correlate of protection against ancestral strains and different variants (34-36).

346

347 ***Concluding remarks***

348 In conclusion, we found that non-Omicron breakthrough infections elicited robust cross-
349 neutralizing activity against Omicron variants (including BA.2) across the antigenic barrier. Most
350 importantly, our study clearly demonstrated that the length of the post-vaccination incubation
351 period, but not the antigenicity of the infecting virus or the upper respiratory viral load, is a critical
352 determinant in expanding the breadth of neutralization to antigenically distinct variants.
353 Additionally, the upper respiratory virus load at the time of infection determines the amount of
354 neutralizing antibody titer produced during the subsequent convalescent phases. Respiratory viral
355 load and the vaccination-infection time interval each showed a variable magnitude of impact for
356 each variant in regard to the induction of neutralizing antibodies in breakthrough-infected
357 individuals. Consequently, antiviral immunity to SARS-CoV-2 is becoming increasingly diverse
358 in individuals with breakthrough infections. Therefore, exploratory studies evaluating factors
359 controlling the quality of the immune response after breakthrough infection can be a useful
360 guidepost for the development of next-generation vaccines with the ability to induce a durable and
361 broad breadth of protective immunity against all SARS-CoV-2 variants. This study highlights the
362 opportunity to develop a variant-proof booster vaccine using an approach that does not rely on
363 antigen design (1).

364 Moreover, it should be noted that control of upper respiratory viral replication in breakthrough
365 cases is more difficult to achieve than control of the vaccination-infection time interval, as viral
366 replication in the respiratory tract is influenced by multiple variables, including the infecting
367 variant, amount of viral exposure, host susceptibility, treatment strategies (including antiviral
368 drugs), innate immune response, and complex pre-existing acquired immunity to SARS-CoV-2.
369 For this, inducing high quality antiviral immunity against SARS-CoV-2 following breakthrough
370 infections is difficult to achieve. Therefore, breakthrough infection should not be considered as an
371 option for boosting immunity.

372

373 **References and Notes**

- 374 1. E. Dolgin, "Pan-coronavirus vaccine pipeline takes form," (Nature reviews. Drug
375 discovery., <https://doi.org/10.1038/d41573-022-00074-6>, 2022).
- 376 2. "Weekly epidemiological update on COVID-19 - 8 March 2022," *Edition 82* (World
377 Health Organization, [https://www.who.int/publications/m/item/weekly-epidemiological-](https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---8-march-2022)
378 [update-on-covid-19---8-march-2022](https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---8-march-2022), 2022).
- 379 3. J. M. Carreño *et al.*, Activity of convalescent and vaccine serum against SARS-CoV-2
380 Omicron. *Nature* **602**, 682-688 (2022).
- 381 4. S. Cele *et al.*, Omicron extensively but incompletely escapes Pfizer BNT162b2
382 neutralization. *Nature* **602**, 654-656 (2022).
- 383 5. W. Dejnirattisai *et al.*, Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant
384 by post-immunisation serum. *The Lancet* **399**, 234-236 (2022).
- 385 6. "Weekly epidemiological update on COVID-19 - 22 February 2022," *Edition 80* (World
386 Health Organization, [https://www.who.int/publications/m/item/weekly-epidemiological-](https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---22-february-2022)
387 [update-on-covid-19---22-february-2022](https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---22-february-2022), 2022).
- 388 7. W. F. Garcia-Beltran *et al.*, mRNA-based COVID-19 vaccine boosters induce neutralizing
389 immunity against SARS-CoV-2 Omicron variant. *Cell* **185**, 457-466.e454 (2022).
- 390 8. F. Schmidt *et al.*, Plasma Neutralization of the SARS-CoV-2 Omicron Variant. *New*
391 *England Journal of Medicine* **386**, 599-601 (2021).
- 392 9. Y. Seki *et al.*, Safety and immunogenicity of the Pfizer/BioNTech SARS-CoV-2 mRNA
393 third booster vaccine dose against the SARS-CoV-2 BA.1 and BA.2 Omicron variants.
394 *Med.*

- 395 10. S. Miyamoto *et al.*, Vaccination-infection interval determines cross-neutralization potency
396 to SARS-CoV-2 Omicron after breakthrough infection by other variants. *Med* **3**, 249-
397 261.e244 (2022).
- 398 11. V. Servellita *et al.*, Neutralizing immunity in vaccine breakthrough infections from the
399 SARS-CoV-2 Omicron and Delta variants. *Cell*, (2022).
- 400 12. A. C. Walls *et al.*, SARS-CoV-2 breakthrough infections elicit potent, broad, and durable
401 neutralizing antibody responses. *Cell* **185**, 872-880.e873 (2022).
- 402 13. P. R. Wratil *et al.*, Three exposures to the spike protein of SARS-CoV-2 by either infection
403 or vaccination elicit superior neutralizing immunity to all variants of concern. *Nature*
404 *Medicine* **28**, 496-503 (2022).
- 405 14. P. Tober-Lau *et al.*, Cross-Variant Neutralizing Serum Activity after SARS-CoV-2
406 Breakthrough Infections. *Emerging Infectious Disease journal* **28**, (2022).
- 407 15. A. Bolze *et al.*, SARS-CoV-2 variant Delta rapidly displaced variant Alpha in the United
408 States and led to higher viral loads. *Cell Reports Medicine* **3**, (2022).
- 409 16. B. Li *et al.*, Viral infection and transmission in a large, well-traced outbreak caused by the
410 SARS-CoV-2 Delta variant. *Nature Communications* **13**, 460 (2022).
- 411 17. P. S. Arunachalam *et al.*, Adjuvanting a subunit COVID-19 vaccine to induce protective
412 immunity. *Nature* **594**, 253-258 (2021).
- 413 18. M. Bergwerk *et al.*, Covid-19 Breakthrough Infections in Vaccinated Health Care Workers.
414 *New England Journal of Medicine* **385**, 1474-1484 (2021).
- 415 19. K. McMahan *et al.*, Correlates of protection against SARS-CoV-2 in rhesus macaques.
416 *Nature* **590**, 630-634 (2021).
- 417 20. Y. Wang *et al.*, Kinetics of viral load and antibody response in relation to COVID-19
418 severity. *The Journal of Clinical Investigation* **130**, 5235-5244 (2020).

- 419 21. S. Lusvarghi *et al.*, SARS-CoV-2 BA.1 variant is neutralized by vaccine booster-elicited
420 serum, but evades most convalescent serum and therapeutic antibodies. *Science*
421 *Translational Medicine* **0**, eabn8543 (2022).
- 422 22. D. J. Smith *et al.*, Mapping the Antigenic and Genetic Evolution of Influenza Virus.
423 *Science* **305**, 371-376 (2004).
- 424 23. A. Z. Mykytyn *et al.*, Omicron BA.1 and BA.2 are antigenically distinct SARS-CoV-2
425 variants. *bioRxiv*, 2022.2002.2023.481644 (2022).
- 426 24. L.-L. Chen, A. W.-H. Chu, R. R.-Q. Zhang, I. F.-N. Hung, K. K.-W. To, Serum
427 neutralisation of the SARS-CoV-2 omicron sublineage BA.2. *The Lancet Microbe*.
- 428 25. F. C. M. Kirsebom *et al.*, COVID-19 Vaccine Effectiveness against the Omicron BA.2
429 variant in England. *medRxiv*, 2022.2003.2022.22272691 (2022).
- 430 26. J. Yu *et al.*, Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants. *New*
431 *England Journal of Medicine*, (2022).
- 432 27. T. A. Bates *et al.*, Antibody Response and Variant Cross-Neutralization After SARS-CoV-
433 2 Breakthrough Infection. *JAMA* **327**, 179-181 (2022).
- 434 28. J. S. Turner *et al.*, SARS-CoV-2 mRNA vaccines induce persistent human germinal centre
435 responses. *Nature* **596**, 109-113 (2021).
- 436 29. R. R. Goel *et al.*, mRNA vaccines induce durable immune memory to SARS-CoV-2 and
437 variants of concern. *Science* **374**, abm0829 (2021).
- 438 30. R. Kotaki *et al.*, SARS-CoV-2 Omicron-neutralizing memory B-cells are elicited by two
439 doses of BNT162b2 mRNA vaccine. *Science Immunology* **0**, eabn8590.
- 440 31. R. R. Goel *et al.*, Efficient recall of Omicron-reactive B cell memory after a third dose of
441 SARS-CoV-2 mRNA vaccine. *Cell*, (2022).

- 442 32. S. Moriyama *et al.*, Temporal maturation of neutralizing antibodies in COVID-19
443 convalescent individuals improves potency and breadth to circulating SARS-CoV-2
444 variants. *Immunity* **54**, 1841-1852.e1844 (2021).
- 445 33. V. G. Hall *et al.*, Delayed-interval BNT162b2 mRNA COVID-19 vaccination enhances
446 humoral immunity and induces robust T cell responses. *Nature Immunology* **23**, 380-385
447 (2022).
- 448 34. D. Cromer *et al.*, Neutralising antibody titres as predictors of protection against SARS-
449 CoV-2 variants and the impact of boosting: a meta-analysis. *The Lancet Microbe* **3**, e52-
450 e61 (2022).
- 451 35. S. Feng *et al.*, Correlates of protection against symptomatic and asymptomatic SARS-CoV-
452 2 infection. *Nature Medicine* **27**, 2032-2040 (2021).
- 453 36. P. B. Gilbert *et al.*, Immune correlates analysis of the mRNA-1273 COVID-19 vaccine
454 efficacy clinical trial. *Science* **375**, 43-50 (2022).
- 455 37. K. Shirato *et al.*, Development of Genetic Diagnostic Methods for Detection for Novel
456 Coronavirus 2019(nCoV-2019) in Japan. *Japanese Journal of Infectious Diseases* **73**, 304-
457 307 (2020).
- 458 38. K. Takahashi *et al.*, Duration of Infectious Virus Shedding by SARS-CoV-2 Omicron
459 Variant–Infected Vaccinees. *Emerging Infectious Disease journal* **28**, 998 (2022).
- 460 39. K. Itokawa, T. Sekizuka, M. Hashino, R. Tanaka, M. Kuroda, Disentangling primer
461 interactions improves SARS-CoV-2 genome sequencing by multiplex tiling PCR. *PLOS*
462 *ONE* **15**, e0239403 (2020).
- 463 40. S. Yamada *et al.*, Assessment of SARS-CoV-2 infectivity of upper respiratory specimens
464 from COVID-19 patients by virus isolation using VeroE6/TMPRSS2 cells. *BMJ Open*
465 *Respiratory Research* **8**, e000830 (2021).

- 466 41. S. Matsuyama *et al.*, Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells.
467 *Proceedings of the National Academy of Sciences* **117**, 7001-7003 (2020).
- 468 42. H. Tani *et al.*, Evaluation of SARS-CoV-2 neutralizing antibodies using a vesicular
469 stomatitis virus possessing SARS-CoV-2 spike protein. *Virology Journal* **18**, 16 (2021).
- 470 43. S. Wilks, "Racmacs: R Antigenic Cartography Macros,"
471 (<https://github.com/acorg/Racmacs>, 2021).
- 472 44. D. Mathew *et al.*, Deep immune profiling of COVID-19 patients reveals distinct
473 immunotypes with therapeutic implications. *Science* **369**, eabc8511 (2020).

474

Acknowledgments:

We thank Akiko Sataka, Asato Kojima, Izumi Kobayashi, Yuki Iwamoto, Yuko Sato, Milagros Virhuez Mendoza, Noriko Nakajima, Kenta Takahashi at NIID for their technical support and Fukumi Nakamura-Uchiyama at Tokyo Metropolitan Bokutoh Hospital and Hidefumi Shimizu at JCHO Tokyo Shinjuku Medical Center for collection of blood samples from vaccinees. We also thank the following healthcare facilities, local health centers, and public health institutes for their contribution in providing us with valuable patient information and samples on breakthrough cases: Aki Health Center, Akiru Municipal Medical Center, Atsugi City Hospital, Akita Research Center for Public Health and Environment, Aomori Jikeikai Hospital, Aso Onsen Hospital, Chiba City Institute of Health and Environment, Chiba Prefectural Institute of Public Health, Chigasaki City Public Health Center, Chuhoku Branch Office for Public Health and Welfare, Daiwa Hospital (Osaka), Fukui Prefectural Institute of Public Health and Environmental Science, Fujimino Emergency Hospital, Fukuoka City Hospital, Gifu City Public Health Center, Gifu Prefectural General Medical Center, Gifu Prefectural Research Institute for Health and Environmental Sciences, Gunma Prefectural Institute of Public Health and Environmental Sciences, Gunma Saiseikai Maebashi Hospital, Hachioji City Public Health Center, Hakodate City Institute of Public Health, Hakodate Public Health Center, Harada Hospital (Hiroshima), Hyogo Prefectural Institute of Public Health Science, Ikegami General Hospital, IMS Fujimi General Hospital, IMS Sapporo Digestive Disease Center General Hospital, Inba Health and Welfare Center, International Goodwill Hospital, International University of Health and Welfare Hospital, International University of Health and Welfare Mita Hospital, Ishikawa Prefectural Central Hospital, Ishikawa Prefecture Health and Welfare Department, Ishikawa Prefectural Institute of Public Health and Environmental Science, Itami City Hospital, Japanese Red Cross Gifu Hospital, Japanese Red Cross Kanazawa Hospital, Japanese Red Cross Kumamoto Hospital, Japanese Red Cross Narita

Hospital, JCHO Kanazawa Hospital, JCHO Nankai Medical Center, JCHO Takanawa Hospital, Juntendo University Hospital, Kaga Medical Center, Kameda Medical Center, Kasai Clinic (Osaka), Kashiwa Public Health Center, Kawachi General Hospital, Kawaguchi Seiwa Hospital, Keio University Hospital, Keiwakai Ebetsu Hospital, Kitakyushu Public Health Center, Kitakyushu Public Health Institute, Kitasato University Kitasato Institute Hospital, Kobe City Nishi-Kobe Medical Center, Kobe Ekisaikai Hospital, Komatsu Municipal Hospital, Koriyama City Public Health Center, Kumamoto City Hospital, Kumamoto City Public Health Center, Kumamoto Prefectural Institute of Public Health and Environmental Science, Kurume-shi Public Health Center, Kyoritsu Narashinodai Hospital, Kyoto City Institute of Health and Environmental Sciences, Kyoto Kujo Hospital, Kyoto Prefectural Institute of Public Health and Environment, Kyowakai Kyoritsu Hospital, Maebashi-shi Public Health Center, Makita General Hospital, Matsui Hospital (Tokyo), Matsumoto City Public Health Center, Mie Prefectural Institute of Public Health and Environmental Sciences, Minami Kaga Health and Welfare Center, Minoh City Hospital, Misato Kenwa Hospital, Mitsui Memorial Hospital, Mizushima Kyodo Hospital, Nadogaya Hospital, Nagano City Public Health Center, Nagano City Public Health Institute, Nagano Environmental Conservation Research Institute, Nagasaki Prefecture Iki Hospital, Nagayama Hospital (Osaka), Nanbu Tokushukai Hospital, Nanshu Orthopedics Hospital, Narita Tomisato Tokushukai Hospital, National Center for Global Health and Medicine, National Hospital Organization Kyoto Medical Center, National Hospital Organization Osaka National Hospital, National Hospital Organization Nagoya Medical Center, Niigata City Health Center, Niigata Prefectural Institute of Public Health and Environmental Sciences, Nippon Medical School Chiba Hokusoh Hospital, Nishinomiya City Public Health Center, Nitta ENT clinic, Obihiro Daichi Hospital, Obihiro Health Center, Oita City Public Health Center, Oita Kouseiren Tsurumi Hospital, Oita Prefectural Institute of Health and Environment, Okayama Kyoritsu Hospital, Osaka

Medical and Pharmaceutical University Hospital, Saiseikai Kanazawa Hospital, Saiseikai Moriyama Municipal Hospital, Saiseikai Yamaguchi Hospital, Saitama City Hospital, Saitama Nishi Kyodo Hospital, Sakura General Hospital (Aichi), Sakura Hospital (Kumamoto), Sapporo Public Health Office, Sasebo City General Hospital, Shibuya Clinic (Ishikawa), Shimane Prefectural Institute of Public Health and Environmental Science, Shimonoseki City Hospital, Shimonoseki Public Health Center, Shin Komonji Hospital, Shin-Yamanote Hospital, Shonan Daiichi Hospital, Suginami Public Health Center, Sumida Ward Public Health Center, Takasaki General Public Health Center, Tama Nambu Chiiki Hospital, Tamashima Central Hospital, Tochigi Prefectural Institute of Public Health and Environmental Science, Tokyo Medical and Dental University Medical Hospital, Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Tokyo Metropolitan Institute of Public Health, Tokyo Women's Medical University Adachi Medical Center, Tonan Hospital, Tsuchiya General Hospital, Tsukuba Central Hospital, Tsurukawa Sanatorium Hospital, Ueda Health and Welfare Office, Utsunomiya City Institute of Public Health and Environment, and Yamanashi Prefectural Institute for Public Health and Environment. We also thank GISAID for the platform to share and compare our data with data submitted globally.

Funding:

Japanese Society for the Promotion of Science Grants-in-Aid for Scientific Research (JSPS KAKENHI) grant 21K20768 (SMiyamoto)

Japan Agency for Medical Research and Development (AMED) grant JP21fk0108104 (TS), JP22fk0108637 (TS), JP20fk0108534 (YT), JP21fk0108615 (YT)

Author contributions:

Conceptualization: SMiyamoto, TA, TS

Methodology: SMiyamoto, TA, AU, TK, SS, HKatano, SI, SMoriyama, SF, YT, TS

Investigation: SMiyamoto, TA, AU, TK, SS, HKatano, SI, AA, SO, TH, YH, SMoriyama, RK, HKinoshita, SY, MS, SF

Data curation: SMiyamoto, TA, TS, SMoriyama, RK, MS

Formal analysis: SMiyamoto, TS

Visualization: SMiyamoto

Funding acquisition: SMiyamoto, YT, TS

Project administration: TS

Supervision: TS

Writing – original draft: SMiyamoto, TS

Writing – review & editing: SMiyamoto, TA, AU, TK, SS, HKatano, SI, AA, TH, YH, SMoriyama, RK, HKinoshita, SY, MS, SF, YT, TS

Competing interests: Authors declare that they have no competing interests.

Data and materials availability: All data are available in the main text or the supplementary materials. The SARS-CoV-2 viruses in this study are available from the National Institute of Infectious Diseases (NIID) under a material transfer agreement with the NIID (Tokyo, Japan).

Supplementary Materials

Materials and Methods

Figs. S1 and S2

Tables S1 and S2

References (37–44)

Alpha variant infection were measured using reverse transcription quantitative polymerase chain reaction (RT-qPCR; left) and the median tissue culture infectious dose (TCID₅₀; right), respectively. Viral titers are shown in viral isolation positive cases. Mean \pm 95% confidence intervals (CIs) are presented. Viral loads were compared using unpaired t-tests. **(B)** Neutralization titers (NTs) in vaccine breakthrough case sera against SARS-CoV-2 pseudoviruses at acute and convalescent phases. Data from the same serum are connected with lines. Mean \pm 95% CIs are presented for each serum titer. Titers between ancestral and newer variants were compared using ANOVA with Dunnett's test. Fold-reductions are indicated above the columns. **(C)** Correlations between viral load in respiratory specimens at the near-diagnosis date and neutralization titers against the indicated variant at acute and convalescent phases. **(D)** Correlations between viral load and fold-changes in neutralization titers in acute and convalescent phases. (C, D) show regression lines, Pearson correlation r values, and significance levels. Statistical significance: * p <0.05, ** p <0.01, *** p <0.001, **** p <0.0001. Dotted lines indicate cutoff values.




Fig. 2. Determinants of neutralization serum titers against SARS-CoV-2 variants in breakthrough infections. (A) Spearman correlation matrix of antibody titers, viral load, and case characteristics for individuals with SARS-CoV-2 breakthrough infections. Neutralizing titers from pseudovirus neutralization tests, viral RNA copies used to represent viral load, and the time from

vaccination to infection were employed herein. Male sex, disease onset, and Delta (vs. Alpha) variant infection were set as dummy variables (1 vs. 0). Spearman correlation r values were indicated using square size and a heat scale. The statistical significance level, corrected using the false-discovery rate (FDR), is shown in the square; * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$. **(B)** Three-dimensional scatter plot of viral RNA load in respiratory specimens at a near-diagnosis date, the time interval from vaccination to infection, and neutralization titers against SARS-CoV-2 variants at the convalescent phase. The dotted planes represent regression planes. Table 1 shows the results of the multiple regression analysis relevant to the findings illustrated herein.




Fig. 3. Antigenic maps of SARS-CoV-2 variants for each serum source. (A) Neutralization titers of sera obtained from individuals vaccinated twice (2vax) or three times (3vax) against

variants of SARS-CoV-2 pseudoviruses. Data from the same serum are connected with lines, and the mean \pm 95% CIs of each serum titer are presented. The titers between the ancestral and newer variants were compared using one-way ANOVA with Dunnett's test; **** p <0.0001. Fold reductions are indicated above columns given statistical significance. Dotted lines indicate cutoff values. **(B)** Antigenic cartography of each serum source for the acute and convalescent phases of breakthrough infection, 2vax, and 3vax (against SARS-CoV-2 variants). The variants are shown as circles and sera are indicated as squares or diamonds. Each square and diamond corresponds to the sera of one individual; colors represent the serum source. Each grid square (1 antigenic unit) corresponds to a two-fold dilution in the neutralization assay. Antigenic distance is interpretable in any direction. The median (interquartile range) of the BA.1-BA.2 variant distance on the map is shown via gray dotted lines.




Fig. 4. Characterization of heterogeneous serum populations based on antigenic map distance, and sources of variation. (A) Antigenic cartography of sera from acute/convalescent phases for breakthrough infections and for those receiving two (2vax) or three vaccines (3vax). Variants are shown as circles and sera are indicated as squares or diamonds. Each square and

diamond corresponds to the sera of one individual; colors represent the serum source. Each grid square corresponds to a two-fold dilution in the neutralization assay. Antigenic distance is interpretable in any direction. **(B)** Clustering the antigenicity of SARS-CoV-2 variants and serum reactions against the variants. The heat map shows the variant-serum distance from the sera. Two antigenic groups and three serum types were divided by k-means clustering. The serum sources are indicated by a color bar on the right. **(C)** Comparison of variant-serum distance from the sera. Distances between the serum sources against 2vax sera were compared using two-way ANOVA with the Sidak test. **(D)** Correlation between the time interval from vaccination to infection and variant-serum distance at the convalescent phase. **(E)** Correlation between viral load in respiratory specimens at a near-diagnosis date and the variant-serum distance of sera at the convalescent phase. Statistical significance: ns, not significant, * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$.

Tables

Table 1. Multiple regression analysis of neutralization titers, including viral load and the time interval from vaccination to infection.

Pseudovirus	Variable	Coefficient	95% CI	P-value
Ancestral (log₁₀ NT)	Time interval (d)	0.003	0.011, -0.006	0.542
	Viral load (log ₁₀ copies)	0.135	0.208, 0.062	<0.001
Alpha	Time interval	-0.002	0.008, -0.011	0.723
	Viral load	0.122	0.203, 0.042	0.004
Beta	Time interval	0.008	0.018, -0.001	0.077
	Viral load	0.123	0.202, 0.043	0.003
Delta	Time interval	-0.002	0.008, -0.011	0.749
	Viral load	0.126	0.206, 0.045	0.003
BA.1	Time interval	0.016	0.024, 0.008	<0.001
	Viral load	0.049	0.118, -0.021	0.166
BA.2	Time interval	0.011	0.02, 0.003	0.012
	Viral load	0.078	0.152, 0.004	0.040

CI, confidence interval

2 **Materials and Methods**

3 Human participants and sampling

4 The characteristics of human participants included in this study are summarized in Table S1.
5 Human plasma samples obtained from vaccinated health care workers with no infections who
6 received two or three doses of BNT162b2 (Pfizer/BioNTech) mRNA vaccine were collected with
7 written informed consent prior to enrollment and ethics approval by the medical research ethics
8 committee of the National Institute of Infectious Diseases (NIID). Blood obtained from vaccinated
9 health care workers was collected in Vacutainer cell preparation tubes (CPT; BD Biosciences,
10 Franklin Lakes, NJ, US) and centrifuged at 1,800 x g for 20 min. Peripheral blood mononuclear
11 cells (PBMCs) were suspended in plasma and harvested into conical tubes, followed by
12 centrifugation at 300 x g for 15 min. The plasma was then transferred into another conical tube
13 and centrifuged at 800 x g for 15 min, and the supernatant was transferred into another tube to
14 completely remove PBMCs.

15 Human serum samples obtained from breakthrough cases were also included in this study. A
16 breakthrough infection was defined according to a positive result in a test detecting SARS-CoV-2
17 RNA or antigen conducted on a respiratory specimen collected ≥ 14 days after the second vaccine
18 dose. Demographic information, vaccination status, and respiratory samples for determining the
19 infecting variant in the breakthrough cases included in this report were collected as part of the
20 public health activity led by NIID under the Infectious Diseases Control Law and were published
21 on the NIID website in order to meet statutory requirements. Sera obtained from breakthrough
22 cases were collected concurrently for clinical testing provided by the NIID (with patient consent),
23 and neutralization assays for this report were performed using residual samples as a research
24 activity with ethics approval by ethics approval from the medical research ethics committee of
25 NIID and informed consent.

26 To examine neutralization, plasma and serum samples were heat-inactivated at 56°C for 30
27 min before use. The median dose interval between the first and second vaccine dose for both
28 vaccinated uninfected individuals and breakthrough cases was 21 days (Table S1).

29 Respiratory specimens were collected through nasal swabs, nasopharyngeal swabs, or saliva
30 samples. Quantitative reverse transcriptase polymerase chain reaction (RT-qPCR) assays were
31 completed at NIID for all respiratory samples to confirm sample quality for genome sequencing
32 and to quantify the viral RNA load.

33 Ethical approval

34 All samples, protocols, and procedures described herein were approved by the Medical
35 Research Ethics Committee of NIID for involving human participants (approval numbers 1178,
36 1275, 1316, and 1321).

37 RNA extraction and RT-qPCR

38
39 RNA was extracted from respiratory samples using the Maxwell RSC miRNA Plasma and
40 Serum kit (Promega, Madison, WI, USA). Quantification cycle (Cq) values (i.e., viral RNA loads)
41 were measured by RT-qPCR using the QuantiTect Probe RT-PCR Kit (Qiagen, Hilden, Germany)
42 targeting the SARS-CoV-2 nucleoprotein (N) region via an NIID-N2 primer/probe set (37). The
43 thermal cycling conditions were as follows: 50°C for 30 min; 95°C for 15 min; and 45 cycles of
44 95°C for 15 s and 60°C for 1 min. The Cq values of samples judged to be negative were analyzed
45 by substituting a Cq value of 45. Cq values were converted to viral nucleoprotein RNA copy
46 numbers/reaction according to a previously reported simple regression line (38). Viral isolation
47

48 and PCR screening for mutations of interest (N501Y, E484K, L452R) were attempted for NIID-
49 N2 primer/probe set positive samples.

50 SARS-CoV-2 viral RNA genome sequencing

51 For respiratory specimens with Cq values of less than 32, SARS-CoV-2 whole viral genome
52 sequences were determined. A primer set modified from the ARTIC Network's V1 primer set
53 (https://github.com/ItokawaK/Alt_nCov2019_primers/tree/master/Primers/ver_N3) was used for
54 conducting multiplex RT-PCR. A DNA library was constructed from the RT-PCR products using
55 the QIAseq FX DNA Library Kit (Qiagen) as described previously (39), and was subjected to next-
56 generation sequencing using the MiSeq System (Illumina, San Diego, CA, USA). Consensus
57 sequences of the viral genome were obtained using the ARTIC field bioinformatics pipeline,
58 following the ARTIC-nCoV-bioinformatics SOP-v1.1.0 ([https://artic.network/ncov-
2019/ncov2019-bioinformatics-sop.html](https://artic.network/ncov-2019/ncov2019-bioinformatics-sop.html), 2020). The consensus sequences were uploaded to the
60 Global Initiative on Sharing All Influenza Data (GISAID; <https://www.gisaid.org/>).

61 PCR screening for mutation detection

62 To support genome sequencing analysis to determine variants, PCR screening for N501Y,
63 E484K, and L452R mutations was completed for all RT-qPCR positive samples. Two in-house
64 PCR assays to detect N501Y and L452R mutations, respectively, had previously been developed
65 at NIID for public health surveillance purposes. To screen for N501Y mutations in the spike (S)
66 region, we designed primers [5'- CTTGTAATGGTGTTRAAGGTTTTAATTGT and 5'-
67 GGTGCATGTAGAAGTTCAAAGAAAG] and TaqMan MGB probes [for N501 detection: 5'-
68 FAM-CCAACACCATTAGTGGGTTG-MGB; for 501Y detection: 5'-VIC-
69 CCAACACCATAAGTGGGTTG-MGB]. To detect L452R mutations in the S domain, we
70 likewise designed primers [5'-GCGTTATAGCTTGGAATTCTAACAATC and 5'-
71 ATCTCTCTCAAAGGTTTGAGATTAGAC] and TaqMan MGB probes [for L452 detection:
72 5'-FAM-ATTATAATTACCTGTATAGATTGT-MGB; for 452R detection: 5'- VIC-
73 TTATAATTACCGGTATAGATTG-MGB]. The final concentrations of the primers and probes
74 were 0.6 μ M and 0.1 μ M, respectively. The reagents and the reaction conditions for RT-qPCR
75 were as described above. For the E484K mutation, a commercial primer/probe for E484K (Takara,
76 Kusatsu, Japan) was used.

77 We defined SARS-CoV-2 variants as follows: (i) Alpha lineage, samples in which E484
78 and 501Y were detected; (ii) Delta lineage, samples in which the 452R was detected; and (iii)
79 undetermined, samples in which the 484K was detected or mutation detections failed. There were
80 no discordant results for these PCR assays in regard to viral genome sequencing in included cases
81 until August 2021.

82 Cells

83 HEK293T cells obtained from the American Type Culture Collection (Manassas, VA, USA)
84 were cultured in Dulbecco's modified Eagle medium (DMEM; Fujifilm, Tokyo, Japan)
85 supplemented with 10% fetal bovine serum (FBS) at 37°C, and were supplied with 5% CO₂.
86 VeroE6/TMPRSS2 cells (JCRB1819, Japanese Collection of Research Bioresources Cell Bank;
87 Osaka, Japan) were maintained in low glucose DMEM (Fujifilm) containing 10% heat-inactivated
88 FBS (Biowest, Nuaille, France), 1 mg/mL geneticin (Thermo Fisher Scientific), and 100 U/mL
89 penicillin/streptomycin (Thermo Fisher Scientific) at 37°C; these cells were supplied with 5% CO₂.

90 Viral isolation and titration

95 Viral isolation was attempted for all RT-qPCR positive cases with available residual
96 respiratory specimens, as described previously (40). Briefly, VeroE6/TMPRSS2 cells (41)
97 (JCRB1819, JCRB Cell Bank) were seeded in 96-well flat-bottom plates, respiratory specimens
98 mixed with DMEM supplemented with 2% FBS and Antibiotic-Antimycotic Solution (Thermo
99 Fisher Scientific) were inoculated in duplicate, and the culture supernatant was changed to fresh
100 medium one day post-infection (d.p.i.) and was incubated at 37°C and supplied with 5% CO₂. On
101 one and five d.p.i., a cytopathic effect was observed. After five days, the supernatant was collected
102 and RT-qPCR using the SARS-CoV-2 direct detection RT-qPCR kit (Takara) was performed in
103 order to confirm the propagation of SARS-CoV-2. The median tissue culture infectious dose
104 (TCID₅₀) in the residual specimens was determined for all viral isolation positive cases.

105 SARS-CoV-2 virus

106 We used the SARS-CoV-2 ancestral strain WK-521 (lineage A, GISAID ID:
107 EPI_ISL_408667) and the Omicron BA.2 variant TY40-158 (lineage BA.2.3, EPI_ISL_9595813)
108 in this study; these variants were isolated using VeroE6/TMPRSS2 cells at NIID with ethics
109 approval provided by the medical research ethics committee of NIID for studies conducted in
110 human subjects (#1178). More specifically, to isolate viruses belonging to the Omicron BA.2
111 variant TY40-158 strain, respiratory specimens collected from individuals screened at airport
112 quarantine stations in Japan and transferred to NIID for whole genome sequencing were subjected
113 to viral isolation using VeroE6/TMPRSS2 cells at NIID.

114 VSV pseudovirus production

115 The vesicular stomatitis virus (VSV) pseudovirus bearing SARS-CoV-2 spike protein was
116 generated as previously described (42). Briefly, the spike genes of SARS-CoV-2 ancestral, Alpha,
117 Beta, and Delta variants were obtained from viral RNA extracted from the SARS-CoV-2 WK-521
118 strain (ancestral strain), QHN002 (Alpha; lineage B.1.1.7, GISAID: EPI_ISL_804008), TY8-612
119 (Beta; lineage B.1.351, GISAID: EPI_ISL_1123289), and TY11-927 (Delta; lineage B.1.617.2,
120 GISAID:EPI_ISL_2158617), respectively, by RT-PCR (PrimeScript II High Fidelity One Step
121 RT-PCR Kit, Takara). The spike gene of the SARS-CoV-2 Omicron variant was obtained from
122 RNA extracted from nasopharyngeal swab specimens from patients infected with the SARS-CoV-
123 2 Omicron BA.2 variant (TY40-158) by RT-PCR, as described above. The cytoplasmic 19 aa-
124 deleted SARS-CoV-2 spike genes were cloned into a pCAGGS/MCS expression vector. HEK293T
125 cells transfected with expression plasmids encoding the SARS-CoV-2 spike genes for the ancestral,
126 Alpha, Beta, Delta, BA.1, and BA.2 variants were infected with G-complemented VSVΔG/Luc.
127 After 24 h, the culture supernatants containing VSV pseudoviruses were collected and stored at -
128 80°C until further use.

129 Electrochemiluminescence immunoassay (ECLIA)

130 Antibody titers for the ancestral spike (S) receptor binding domain (RBD) and nucleoprotein
131 (N) were measured using Elecsys Anti-SARS-CoV-2 S (Roche, Basel, Switzerland) and Elecsys
132 Anti-SARS-CoV-2 S (Roche) kits according to manufacturer instructions.

133 VSV pseudovirus-based neutralization assay

134 Neutralization of SARS-CoV-2 pseudoviruses was performed as described previously (10,
135 32). Briefly, serially diluted serum (with five-fold serial dilution of serum from participants with
136 second vaccinations, or eight-fold serial dilution of serum from breakthrough infected patients and
137 participants with third vaccinations, starting at a 1:10 dilution) was mixed with an equal volume
138 of VSV pseudovirus bearing SARS-CoV-2 spike protein and incubated at 37°C for 1 h. The
139
140
141
142

143 mixture was then inoculated into VeroE6/TMPRSS2 cells seeded on 96-well solid white flat-
144 bottom plates (Corning; Corning, NY, USA). At 24 h post-infection, the infectivity of the VSV
145 pseudovirus was assessed by measuring luciferase activity using a Bright-Glo Luciferase Assay
146 System (Promega) and a GloMax Navigator Microplate Luminometer (Promega). The reciprocal
147 half-maximal inhibitory dilution (ID₅₀) is presented as the serum neutralization titer.

148 Live virus neutralization assay

149 Live virus neutralization assays were performed as described previously (10, 32). Briefly,
150 serum samples were serially diluted (via two-fold dilutions starting from 1:5) in high-glucose
151 DMEM supplemented with 2% FBS and 100 U/mL penicillin/streptomycin and were mixed with
152 100 TCID₅₀ SARS-CoV-2 viruses (WK-521, ancestral strain; and TY40-158, Omicron BA.2
153 variant), followed by incubation at 37°C for 1 h. The virus-serum mixtures were placed on
154 VeroE6/TMPRSS2 cells seeded in 96-well plates and cultured at 37°C with 5% CO₂ for five days.
155 After culturing, the cells were fixed with 20% formalin (Fujifilm) and stained with crystal violet
156 solution (Sigma-Aldrich, St. Louis, MO, USA). Neutralization titers were defined as the geometric
157 mean of the reciprocal of the highest sample dilution that protects at least 50% of the cells from a
158 cytopathic effect from two to four multiplicate series. Since sera from individuals who suffered
159 from breakthrough infections were limited in quantity, this assay was performed only once. All
160 experiments using authentic viruses were performed in a biosafety level 3 laboratory at NIID.
161

162 Antigenic cartography

163 Antigenic maps based on neutralization titers against SARS-CoV-2 pseudoviruses were
164 created using the *Racmacs* R function (The R Project for Statistical Computing, Vienna, Austria)
165 with 2,000 optimizations (22, 43). Each grid square (1 antigenic unit) corresponded to a two-fold
166 dilution in the neutralization assay. Antigenic distance (i.e., map distance) was used as the variant-
167 serum distance (<https://acorg.github.io/Racmacs/articles/intro-to-antigenic-cartography.html>).
168 Medians and interquartile ranges of the distances between BA.1 and BA.2 variants were calculated
169 by Pythagorean theorem using the coordinates of antigenic maps in optimization steps. Heatmaps
170 were created to visualize variant-serum distances using the *ComplexHeatmap* R function.
171

172 Statistical analysis

173 Data analysis and visualization were performed using GraphPad Prism 9.3.1 (San Diego, CA,
174 USA) and R 4.1.2. Measurements below the detection limit, excluding Cq values, were converted
175 to half the detection limit. For statistical analysis, unpaired t tests, one-way analysis of variance
176 (ANOVA) with Dunnett's test, and two-way ANOVA with the Sidak test were used to compare
177 viral loads, antibody titers, and variant-serum distances. Pearson correlation coefficients were used
178 to assess correlations between continuous variables. Statistical significance was set at $p < 0.05$. In
179 correlation matrix analyses, Spearman correlations between variables were calculated with false
180 discovery rate (FDR) correction and were visualized using the *psych* and *corrplot* R functions, as
181 described previously (44). Coefficients were indicated using square size and the aforementioned
182 heat scale.
183

184 In multiple regression analysis, each neutralization antibody titer against ancestral and newer
185 SARS-CoV-2 variants in convalescent sera was regressed against respiratory viral load (x_1 , viral
186 RNA copies) at a near-diagnosis date as well as the time interval (x_2 , days) from vaccination to
187 infection. The model for neutralization titer y for participant i can be written as follows:

$$188 \quad \text{Log}_{10} y_i = \beta_0 + \beta_1 \log_{10} x_{1i} + \beta_2 x_{2i} + \varepsilon_i$$

189 β_0 represents the y -intercept; and β_1 , β_2 , and ε represent the slope coefficients and error term,
190 respectively. These analyses and visualizations were performed using the *stats* and *scatterplot3d*
191 R functions.

192

193




Fig. S1. Supplemental characterizations of respiratory specimens and sera from individuals with SARS-CoV-2 vaccine-breakthrough infections.

(A) Correlations between viral RNA copies and viral titers. (B) Anti-nucleoprotein (N) and anti-spike receptor binding domain (S RBD) antibody titers in breakthrough cases by days from diagnosis and days from symptom onset. Gray areas indicate 4-7 days since diagnosis or onset. (C) Neutralization titers (NTs) of breakthrough case sera against variants of SARS-CoV-2 live viruses at acute and convalescent phases. Data from the same serum are connected with lines, and means±95% confidence intervals (CIs) for each serum titer are presented herein. Titers were compared between ancestral and BA.2 variants using unpaired t-tests. Fold reductions are indicated above the columns. (D) Correlations of neutralization titers against pseudoviruses and live viruses. (E) Comparisons of neutralization titers between background variant types in breakthrough infections against SARS-CoV-2 pseudovirus variants. Titers were compared between background variant types using two-way analysis of variance (ANOVA) with the Sidak test. (A, D) Regression lines, Pearson correlation r values, and statistical significance levels are shown herein. Statistical significance: * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$. Dotted lines indicate cutoff values.

194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210

223
224

Table S1.
Medical and demographic characteristics of the participants included in this study.

Sample	Breakthrough infection			2 vaccination	3 vaccination
	Serum (acute)	Serum (convalescent)	Respiratory specimen	Plasma	Plasma
N	26	51	220	20	19
Age (y)	58 (35, 78)	36 (26, 58)	50 (30, 74)	42 (32, 48)	34 (31, 40)
Male sex	17 (65%)	35 (69%)	141 (64%)	4 (20%)	9 (47%)
Vaccine (2 doses)					
BNT162b2	24 (92%)	50 (98%)	189 (86%)	20 (100%)	20 (100%)
Not listed	2 (8%)	1 (2%)	31 (14%)	0 (0%)	0 (0%)
Severity					
Asymptomatic	6 (21%)	26 (46%)	64 (28%)	NA	NA
Mild	19 (68%)	29 (51%)	143 (63%)	NA	NA
Moderate*	3 (11%)	2 (4%)	21 (9%)	NA	NA
Dose 1 to dose 2 interval (days)	21 (21, 21)	21 (21, 21)	21 (21, 21)	21 (21, 21)	21 (21, 21)
Infection to sera collection (days)	1 (0, 2)	14 (11, 16)	NA	NA	NA
Infection to respiratory specimen collection (days)	0 (0, 2)	0 (0, 0)	0 (0, 0)	NA	NA
Dose 2 to infection (days)	46 (29, 62)	41 (30, 62)	50 (31, 73)	NA	NA
Dose 2/3 to sera collection (days)	48 (32, 62)	64 (44, 75)	NA	32 (29, 34)	35 (35, 35)
Dose 2 to dose 3 interval (days)	NA	NA	NA	NA	245 (245, 246)
Infection lineage					
Alpha	6 (23%)	24 (47%)	50 (23%)	NA	NA
Delta	12 (46%)	14 (27%)	136 (62%)	NA	NA
R.1	0 (0%)	0 (0%)	2 (1%)	NA	NA
Undetermined	8 (31%)	13 (25%)	32 (15%)	NA	NA
Period of infection	Apr. 10 - Aug. 20, 2021	May 14 - Aug. 20, 2021	Apr. 10 - Aug. 25, 2021	NA	NA

Median (interquartile range); n (%)

*Moderate includes individuals who required oxygen

225
226

227
228
229
230

Table S2.

Individual characteristics, upper respiratory viral loads, and serum titers of the participants included in this study.